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Introduction: Pulmonary hypertension (PH) is a serious complication of lupus. The
effectiveness of current vasoactive therapy has not been well described.
Methods: Retrospective analysis of 12 patients with lupus-associated PH (age 43710
years, mean7SD, all female) treated with pulmonary vasodilators.
Results: At baseline, patients had severe PH: median six-minute walk distance (6MWD)
266m (95% confidence interval [CI], 106 to 362); functional class III (n ¼ 7) and IV (n ¼ 5);
mean pulmonary artery pressure (mPAP) 52mmHg and cardiac index 2.23 L/min/m2. Eight
patients were started on epoprostenol and 2 each on bosentan or treprostinil. After a mean
follow-up of 41725 months, 5 patients were on combination therapy (3 epoprostenol plus
bosentan, 1 treprostinil plus bosentan, 1 bosentan plus sildenafil) and 7 were on
monotherapy (2 epoprostenol, 4 bosentan, 1 sildenafil); 6MWD increased by 139m (95% CI,
36 to 259, p ¼ 0.007), 8 patients were functional class I or II and 4 were class III; right
ventricular systolic pressure (RVSP) decreased by 22mmHg (95% CI, 6 to 36; p ¼ 0.012),
mPAP decreased by 18mmHg (95% CI, 8 to 29; p ¼ 0.014), and cardiac index increased by
1.44 L/min/m2 (95% CI, 0.76 to 2.08; p ¼ 0.016). There was no mortality or need for lung
transplantation. Therapy was well tolerated.
Conclusions: Vasoactive therapy can achieve sustained clinical and hemodynamic
improvement in lupus-associated PH.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Pulmonary hypertension (PH) is a well-recognized complica-
tion of collagen vascular diseases. This association is better
appreciated for patients with the scleroderma spectrum of
disease, and less so for patients with systemic lupus
erythematosus (SLE). The prevalence of PH in patients with
SLE has varied in different series1–4 most likely as a result of
increasing awareness, wider access to better noninvasive
measurements of right ventricular systolic pressure (RVSP),
and differences in the way PH has been defined. In a recent
study, using a cutoff of 40mmHg for RVSP measured by
Doppler echocardiography, Johnson et al.5 found a pre-
valence of 14% in a cohort of 129 patients with SLE, similar
to estimates in systemic sclerosis. Thus, SLE-associated PH
appears to be more common than previously recognized.
The etiology of PH in patients with SLE is multi-factorial and
arteriopathy involving the pulmonary vasculature, with
increasing pulmonary vascular resistance and vasoconstric-
tion, is felt to play a role.2,6
Treatment of SLE-associated PH is controversial, and
includes vasodilators, immunosuppressive agents or a
combination of both.7–17 However, therapeutic decisions
remain guided by scant literature comprised of case reports
or small case series. Several studies have suggested a
guarded prognosis for SLE-associated PH, with substantial
mortality.2,18 These data precede the introduction of
selective pulmonary vasodilators.
We describe a single center series of 12 patients with SLE-
associated PH treated with parenteral and oral vasoactive
agents, with a focus on long-term outcomes.Methods
The study was approved by our Institutional Review Board.
Medical records of patients followed in the PH clinic at the
Cleveland Clinic were retrospectively reviewed to identify
patients who met the revised American Rheumatism
Association diagnostic criteria for SLE.19 All patients had
undergone a work-up to rule out other causes of PH as
recommended by current guidelines.20
Medical records were analyzed for clinical parameters,
laboratory testing, 6-min walk test, echocardiographic, and
right heart catheterization (RHC) data at baseline, 3 and 6
months, 1, 2 and 3 years after initiation of vasodilator
therapy and at last follow-up.
Data at individual time points are presented as means and
95% confidence intervals (CI) based on the T distribution. For
each variable, the last follow-up value was defined as the
most recent available value. Absolute change from baseline
to follow-up was also described using the mean and a 95% CI.
Each variable is summarized at individual time points using
all available data, but comparison of a follow-up time point
to baseline uses only patients with data at both follow-up
and baseline in a paired fashion. For the 6-min walk distance
(6MWD), we assigned a result of 0m at baseline to patients
who were admitted to the hospital with symptoms of overt
right-sided heart failure for emergent initiation of vasodi-
lator therapy and were unable to perform the test.21,22 We
used medians and CI based on signed-rank tests to describe
the walk distances at individual time points, as well aschange from baseline. The Wilcoxon signed-rank test was
used to assess the statistical significance of changes from
baseline to follow-up, and to produce the corresponding CI.
R version 1.9.0 was used to perform the tests.Results
Baseline characteristics are shown in Table 1. All cases were
women, with a mean age of 43710 years. Mean time since
diagnosis of SLE to the diagnosis of PH was 9.25 years. At the
time of the diagnosis of PH, 10 patients were on immuno-
suppressive therapy, most commonly prednisone or hydro-
xychloroquine. During the study period 9 patients were on
warfarin therapy. Three patients (#2, 6 and 10) had a lupus
flare during the study period, and in 1 patient (#10) an SLE
flare occurred shortly before the diagnosis of PH was made.
Pulmonary function testing results were available for 10
patients. Flows and volumes were normal in 7 and showed
moderate restriction (n ¼ 1), mild obstruction (n ¼ 1), or
severe obstruction with restriction (n ¼ 1) in the others.
Carbon monoxide diffusion capacity (DLCO) was available in
6 patients and was moderately (n ¼ 2) or severely (n ¼ 3)
reduced in the majority. Interestingly, the 3 patients
with intermediate or high probability ventilation perfusion
scans had negative pulmonary angiograms for pulmonary
embolism.
Table 2 outlines clinical, hemodynamic and treatment
characteristics of the patients. At baseline, 7 patients had
New York Heart Association (NYHA) class III and 5 had class IV
symptoms, and median 6MWD was 266m (95% CI, 106 to
362). Four patients were in overt right-heart failure and
unable to perform the 6-min walk. Mean RVSP estimated by
Doppler echocardiography was 77mmHg (95% CI, 65 to 88).
All patients had evidence of right ventricular dilation, but
no pericardial effusions were detected by echocardiography.
Baseline RHC information was available for all patients. One
patient (#3) was diagnosed with PH during a pulmonary
angiogram and refused RHC. Mean right atrial pressure was
12mmHg (95% CI, 7 to 18), mean pulmonary artery pressure
(mPAP) was 52mmHg (95% CI, 46 to 58), and cardiac index
was 2.23 L/min/m2 (95% CI, 1.89 to 2.57).
Eight patients were started on epoprostenol, 2 on
subcutaneous treprostinil, and 2 on bosentan. Mean
follow-up was 41725 months (mean7SD). Most patients
demonstrated an impressive response to therapy (Table 2,
Figs. 1–3). After 3 months, 6MWD increased by a median of
57m (95% CI, 7 to 235, p ¼ 0.04) and 10 patients had
improved by at least one NYHA functional class.
At last follow-up, 8 patients were NYHA class I or II and 4
were NYHA class III (Fig. 1). Four patients were on
combination therapy including a parenteral prostacyclin (3
on epoprostenol plus bosentan, and 1 on subcutaneous
treprostinil plus bosentan), 1 patient was on bosentan plus
sildenafil, and 7 patients were on single-drug therapy (2 on
epoprostenol, 4 on bosentan and 1 on sildenafil). Compared
to baseline, 6MWD increased by a median of 139m (95% CI,
36 to 259; p ¼ 0.007). When analyzing only those patients
who had a baseline 6MWD (n ¼ 8), the improvement to last
follow-up was a median of 55m (95% CI, 9 to 134,
p ¼ 0.11). RVSP decreased by a mean of 22mmHg (95% CI,
6 to 36; p ¼ 0.012), mPAP decreased by 18mmHg (95% CI,
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Table 1 Baseline clinical features of 12 patients with lupus-associated pulmonary hypertension.
Pt Age
(years)
Raynaud’s Positive
antibodies
SLE medications T1
(years)
Presenting
symptoms
Chest CT VQ scan
1 29 No ANA and ds-DNA Hydroxychloro-
quine
0 Syncope Normal
parenchyma
Low probability
2 37 Yes ANA, ds-DNA,
Smith and RNP
Prednisone and
hydroxychloro-
quine
6 Dyspnea Normal
parenchyma
Large symmetric
mismatched
defects in both
upper lobes. PA
gram showed no
filling defects
3 53 No ANA Prednisone,
hydroxychloro-
quine and
methotrexate
24 Dyspnea
and
syncope
Normal
parenchyma
Low probability
4 49 NA ANA Prednisone and
hydroxychloro-
quine
15 Dyspnea Bilateral lower
lobes interstitial
infiltrates; mild
pericardial
thickening
Low probability
5 42 No ANA, anti-
phospholipid and
RNP
Prednisone 2 Dyspnea Normal NA. PA gram
negative for PE
6 40 Yes ANA, ds-DNA,
Smith and RNP
Prednisone and
cyclophosphamide.
methotrexate
(discontinued)
3 Dyspnea Scattered small
patchy
infiltrates, small
bilat pleural
effusions, small
pericardial
effusion
NA
7 56 Yes ANA, ds-DNA,
Smith
Hydroxychloro-
quine
20 Dyspnea Normal. No PE NA
8 46 Yes NA None (previously
on prednisone,
cyclophosphamide
and hydroxychlo-
roquine)
14 Dyspnea,
chest pain
and
syncope
Sub-segmental
atelectasis RML,
RLL pleural
thickening
Intermediate
probability. PA
gram negative for
PE
9 61 Yes ANA, ds-DNA None 0 Dyspnea Normal Normal
10 38 NA ANA, ds-DNA, IgM
cardiolipin
Prednisone;
previously on
mycophenolate
mofetil
8 Dyspnea Scattered hazy
opacities
bilaterally,
otherwise normal
Low probability
11 34 Yes ANA, ds-DNA,
Smith, IgG
cardiolipin, lupus
AC and RNP
Prednisone,
hydroxychloro-
quine and
mycophenolate
mofetil
14 Dyspnea Minimal bilateral
basilar
atelectasis and
fibrosis
High probability,
but PA gram
negative for PE
12 30 No ANA, ds-DNA Hydroxychloro-
quine and
mycophenolate
mofetil
5 Dyspnea Vague patchy RLL
alveolar
infiltrate,
pericardial
effusion. No PE
NA
Abbreviations: Pt, patient; SLE, systemic lupus erythematosus; T1, time from diagnosis of SLE to diagnosis of pulmonary hypertension;
CT, computed tomography; VQ, ventilation-perfusion; ANA, antinuclear antibodies; ds-DNA, double-stranded deoxyribonucleic acid;
RNP, ribonucleoprotein; RML, right middle lobe; RLL, right lower lobe; PA gram, pulmonary angiogram; PE, pulmonary embolism; NA,
not available.
SLE-associated PH and vasoactive therapy 21018 to 29; p ¼ 0.014), and cardiac index increased by
1.44 L/min/m2 (95% CI, 0.76 to 2.08; p ¼ 0.016) (Fig. 2).
Repeat RHC data were not available in all patients, as
depicted in Fig. 2, but where available (n ¼ 8 for mPAP,n ¼ 7 for cardiac index), it showed a decrease in mPAP and
an increase in cardiac index. Three patients (see Table 2)
were transitioned from a parenteral prostacyclin to oral
therapy (2 to bosentan and 1 to bosentan plus sildenafil) and
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Table 2 Clinical and hemodynamic features at baseline and follow up of 12 patients with lupus-associated pulmonary hypertension.
Pt NYHAy 6MWDy
(m)
RHCy (RAP, mPAP,
CI, PCWP, PVR)
PH medications Duration of each therapy Follow-up in
months
6MWDz
(m)
RHCy (RA, mPAP,
CI, PCWP, PVR)
1 III 454 2 Treprostinil+bosentan 11 months+9months 11 588 NA
40
2.3
2
10
2 III 354 14 Epoprostenol+bosentan 42 months+33 months 42 444 NA
55
2.1
10
13
3z III 473 7 Treprostinil (discontinued);
bosentan
20 months; 27 months 56 525 3
59 50
2.7 3.1
16 5
9 8
4 III 319 9 Epoprostenol 46 months 46 518 8
44 28
2.1 4.0
15 10
8 2
5 III 288 NA Bosentan 21 months 18 270 10
40 32
NA 3.4
16
3
6 IV 0 26 Epoprostenol 81 months 81 447 6
67 22
1.3 3.3
13 6
20 2
7 IV 0 8 Epoprostenol+bosentan 106 months+36 months 82 355 10
61 57
2.2 3.7
7 20
13 6
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8 III 244 24 Epoprostenol (discontinued);
sildenafil
3 months; 20 days 3 261 NA
50
1.8
12
10
9 IV 212 6 Treprostinil (discontinued);
epoprostenol+bosentan
1 months; 52 months+30 months 52 236 10
47 35
3.0 4.1
10 7
6 4
10z IV 0 NA Epoprostenol (discontinued);
bosentan+sildenafil
9 months; 25 months+24 months 34 162 12
48 36
1.7 2.7
10 11
11 4
11z III 404 16 Epoprostenol (discontinued);
bosentan
36 months; 29 months 41 370 5
65 28
2.4 4.2
14 10
9 2
12 III 0 12 Bosentan 19 months 19 363 NA
50
2.7
11
10
Abbreviations: NYHA, New York Heart Association; 6MWD, 6-min walk distance; TTE, transthoracic echocardiogram; RVSP, right ventricular systolic pressure (mmHg); RHC, right heart
catheterization; RAP, right atrial pressure (mmHg); mPAP, mean pulmonary artery pressure (mmHg); CI, cardiac index (L/min/m2); PCWP, pulmonary capillary wedge pressure; PVR,
pulmonary vascular resistance (Woods units); PH, pulmonary hypertension; NA, not available.
Last follow-up adjusted to the six-minute walk distance.
yBaseline.
zLast follow-up.
yTiming of repeat RHC was variable; it occurred on average 17.5 months after baseline (range, 2–60 months).
zTransitioned from parenteral prostacyclin to oral therapy.
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Figure 2 Change in 6-min walk distance, right ventricular systolic pressure, mean pulmonary artery pressure, and cardiac index
from baseline to last follow-up (mean 41 months). Follow-up mean pulmonary artery pressure and cardiac index occurred on average
17.5 months after baseline (range, 2–60 months). The lateral diamonds and bars represent the medians and 95% confidence intervals
(CI) for the 6-min walk distance and means and 95% CI for the other parameters.
Figure 1 New York Heart Association functional class at
baseline and throughout follow-up. Abbreviation: NYHA, New
York Heart Association.
Figure 3 Change in 6-min walk distance and right ventricular
systolic pressure over time. Data presented as medians and 95%
confidence intervals (CI) for the 6-min walk distance and means
and 95% CI for the right ventricular systolic pressure. Abbrevia-
tions: 6-MWD, 6-min walk distance; RVSP, right ventricular
systolic pressure.
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months. Thus, vasoactive therapy accomplished early
and sustained clinical and hemodynamic benefits in this
group of patients, as depicted in Fig. 3 regarding 6MWD
and RVSP.
There was no mortality during the follow-up time and no
patient needed to undergo lung transplantation. One
patient (#8) on epoprostenol developed severe thrombocy-
topenia and a skin rash that resolved after discontinuation
of the drug and transition to oral bosentan and sildenafil.
There were no cases of abnormal liver function tests with
bosentan. Otherwise, side effects were typical of the known
drugs’ profiles.Discussion
We describe a series of patients with SLE-associated PH
treated with parenteral and oral vasoactive agents. Our
patients had severe SLE-associated PH and demonstrated
clinical and hemodynamic benefits as early as 3 months after
the initiation of therapy, which were sustained over a mean
follow-up of 41 months. This is the largest series to show
that benefits obtained initially with parenteral and oral
vasoactive agents, can be sustained long-term in patients
with SLE-associated PH.
Time between diagnosis of SLE and PH was variable, was
not necessarily related to disease activity2,15 and PH was the
presenting feature leading to a diagnosis of SLE in 2
patients. Presenting symptoms and signs in our patients
were non-specific.
Few studies have reported pulmonary function test results
in these patients. One report7 found normal flows and
volumes with a moderately decreased DLCO. Most of our
patients had normal flows and volumes; however, when
available, the DLCO was usually abnormal. Larger studies in
patients with SLE with and without PH are required to better
delineate the significance of this finding, and whether this
can be used as an early indicator of a high likelihood of PH,
similar to patients with scleroderma.23 Some authors14 have
attempted to divide patients with PH and SLE into primary
and secondary PH, i.e., those without and with significant
pulmonary or left-sided cardiac disease, respectively. Only
one of our patients (#3) had significant interstitial lung
disease with moderate to severe restriction and may be
characterized as secondary PH, and none had significant
left-sided cardiac disease. The lack of left-sided heart
disease, pulmonary emboli and interstitial lung disease
indicates that these patients were symptomatic from
pulmonary vascular involvement due to SLE.
Echocardiography was performed serially in all of our
patients. Transthoracic echocardiography can be relatively
accurate in predicting pulmonary arterial pressure in this
patient population.24 However, the shortcomings of Doppler
measurement of pulmonary artery systolic pressure are well
recognized.20 In view of the dearth of information about the
extent of hemodynamic abnormalities and how these relate
to baseline characteristics and response to therapy in
patients with SLE-associated PH, it is our recommendation
that all patients with SLE suspected to have PH should
undergo RHC prior to initiation of therapy.PH in the setting of collagen vascular disorders is
commonly associated with a poor prognosis.25 This has been
shown by data mainly from patients with PH associated with
scleroderma.21,26,27 It is also recognized that patients with
scleroderma have a significantly worse prognosis if they
develop PH.28 Data in patients with SLE-associated PH are
scant and suggest that PH in the setting of SLE carries a poor
prognosis.2,18,29 However, these data precede the use of
modern pulmonary vasoactive therapy.
Multi-center trials21,22,30–32 have led to the approval of
parenteral, inhaled, and oral vasoactive agents that act as
pulmonary vasodilators and may also possess anti-thrombo-
tic, anti-fibrotic and anti-mitogenic properties. Recent
evidence suggests that patients with PH may obtain
sustained benefit with the use of monotherapy33–35 or
combination therapy36–38 in the appropriate clinical setting.
In our series, patients had a significant response to
parenteral and/or oral vasodilators with improved func-
tional parameters and hemodynamics. Recently, Chung
et al.7 found a significantly worse survival in 20 patients
with SLE-associated PH compared to 34 with idiopathic PH
(3- and 5-year survival rates of 45% and 17% vs. 73% and 68%,
respectively). However, only 11 SLE-PH patients (55%) were
treated with a vasoactive agent, namely beraprost, which
has been shown to be ineffective long-term in patients with
PH.39 In addition, only 3 patients were on warfarin therapy,
and half of the SLE patients did not receive a RHC to confirm
the diagnosis. In our series there was no mortality after a
mean follow-up of 41 months, no patient required lung
transplantation and 3 patients were transitioned from
parenteral prostacyclin to oral therapy with continued
improvement. These findings, coupled with the significant
clinical and hemodynamic response observed, suggest that,
if appropriately treated with current pulmonary vasodilator
therapy, this patient population may have a better prognosis
than previously recognized.
This kind of clinical and hemodynamic response has been
previously reported. Robbins et al.15 described a series of 6
patients with SLE-associated PH treated with continuous
intravenous epoprostenol. Baseline clinical and hemody-
namic features were remarkably similar to the subjects in
our series, as was the magnitude of both the clinical and
hemodynamic response.
Therapy was well tolerated in our series. Only 1 patient
developed thrombocytopenia felt to be related to epopros-
tenol, which resolved upon discontinuation of the drug.
Close monitoring is warranted though, since life-threatening
thrombocytopenia in SLE patients treated with epoprostenol
has been reported.16
Only 3 patients experienced a lupus exacerbation during
the course of follow-up. There are reports of improvement
in SLE-associated PH with immunosuppressive ther-
apy.10,12,17 However, other reports suggest poor or no
response.7,40 Benefit has also been reported when treating
with a combination of vasodilators and immunosuppressive
agents.8,9 Most of our patients were on stable doses of
immunosuppressants or were treated with increasing doses
for a short period of time, without appreciable changes in
their PH. It is clear from our series that patients with SLE-
associated PH have a favorable short- and long-term
response to vasoactive therapy with both parenteral and
oral agents and, until larger studies are performed, these
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The role of immunosuppressive agents either alone or in
combination with vasoactive agents requires further study.
This report has the limitations of any retrospective case
series. We did not have a control population and not all
patients had follow-up RHC. Treatment was heterogeneous;
however, we decided to include all patients to draw
attention to the fact that patients had an excellent response
to both parenteral and oral agents of different classes and
that benefit was sustained despite the necessity to change
therapies in some patients. Reports like this can provide
information about current clinical practice and can guide
the design of prospective, controlled, randomized trials.
In conclusion, we present a series of patients with SLE-
associated PH who showed improvement in their clinical and
hemodynamic parameters with the use of pulmonary
vasodilators. This improvement was sustained over a mean
follow-up of 41 months. These findings suggest that, if
appropriately diagnosed and treated, these patients may
have a better prognosis than previously suspected, espe-
cially in the era of modern vasoactive therapy. Prospective
randomized trials of vasoactive agents specifically for
patients with SLE-associated PH are warranted.
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